

ForPatients

by Roche

Chronic Obstructive Pulmonary Disease (COPD)

A Study Of ¹²#XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT04353661 GE42063

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI. The sensitivity of XE-MRI to detect COPD progression will be compared with standard clinical assessment measures including standard lung function tests, 6 minute walk test, and patient reported quality of life.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT04353661 GE42063
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥40 Years

Healthy Volunteers
No
